Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 16, Issue 1, Pages 93-102Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/108497801750096122
Keywords
monoclonal antibody; epidermal growth factor receptor; immunotherapy; phase I clinical trial; tyrosine kinase inhibitors
Ask authors/readers for more resources
Ior egf/r3, a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR) was generated at the Cuban Institute of Oncology. Immunoscintigraphic studies in 148 patients with this 99-m Technetium (Tc-99) labeled mAb, showed a high sensitivity and specificity for in vivo detection of epithelial tumors. To study safety, pharmacokinetic and immunogenicity of ior egf/r3 at high doses, a phase I clinical trial was conducted. Nineteen patients with advanced epithelial tumors received 4 mAb intravenous infusions at 6 dose levels: from 50 to 500 mg. Previously, immunoscintigraphic images using the same mAb labeled with Tc-99 were acquired Blood samples were collected for pharmacokinetic analysis and HAMA response. After mAb therapy objective response was classified according to WHO criteria. Ior egf/r3 was well tolerated in spite of the high-administered doses. Only a severe adverse reaction consisting of hypotension and lethargy was observed. In 13 patients, selective accumulation of Tc-99-labeled mAb was observed at the site of the primary tumor or the metastasis. Pharmacokinetic analysis revealed that elimination half-life and the area under the time-concentration curve increased linearly with dose. HAMA response was detected in 17 patients. After 6 months of mAb therapy 4 patients had stable disease. One patient had a tumor partial remission after 3 cycles of ior egf/r3.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available